Saxagliptin/metformin

Saxagliptin/metformin is a combination drug used for the treatment of type 2 diabetes. It contains two active ingredients: saxagliptin and metformin. The drug is marketed under the brand name Kombiglyze XR by AstraZeneca.

Indications

Saxagliptin/metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both saxagliptin and metformin is appropriate.

Mechanism of Action

Saxagliptin works by increasing the levels of certain natural substances that lower blood sugar when it is high. Metformin works by decreasing glucose (sugar) production in the liver and absorption in the intestine, and by improving insulin sensitivity by increasing peripheral glucose uptake and utilization.

Side Effects

Common side effects of saxagliptin/metformin include upper respiratory tract infection, urinary tract infection, and headache. Serious side effects may include lactic acidosis, pancreatitis, and heart failure.

Contraindications

Saxagliptin/metformin is contraindicated in patients with severe renal impairment, metabolic acidosis, or diabetic ketoacidosis.

Interactions

Saxagliptin/metformin may interact with other drugs such as digoxin, rifampin, and topiramate.

Dosage

The dosage of saxagliptin/metformin is based on the patient's medical condition, kidney function, and response to treatment.

See Also

• Type 2 diabetes
• Saxagliptin
• Metformin
• AstraZeneca

Saxagliptin/metformin Resources
Latest articles Most recent articles Ongoing trials	Wikipedia